Sanofi says it is cooperating with gov't on dengue vaccine

December 4, 2017
Sanofi says it is cooperating with gov't on dengue vaccine
Dr. Ng Su-Peing, global medical head at Sanofi Pasteur, the manufacturer of dengue vaccine Dengvaxia, speaks at a news conference in suburban Taguig city, east of Manila, Philippines Monday, Dec. 4, 2017. The manufacturer of the dengue vaccine whose use was suspended by the Philippines last week after a study showed risks of severe cases in people without previous infection says it is working to resolve those fears. (AP Photo/Bullit Marquez)

The manufacturer of a dengue fever vaccine that was suspended in the Philippines after a new study showed a greater risk of severe cases in people without previous infection said Monday it is working with authorities to address fears and share the new information.

The Philippine Department of Health put on hold its 3.5 billion peso ($69.5 million) public dengue immunization drive launched last year— the world's first such public program—after the study was released last week.

French-based Sanofi Pasteur said its long-term follow-up study of its Dengvaxia vaccine showed sustained benefits for up to six years for those who had previous dengue , but that people who never had dengue had an increased risk of a severe case and hospitalization from the third year after immunization.

More than 730,000 public school children aged 9 and above in three Philippine regions with high rates of have received at least the first dose of Dengvaxia, the first licensed dengue vaccine.

"Today if you know somebody without previous infection, we would not recommend vaccination," said Dr. Ng Su-Peing, global medical head at Sanofi Pasteur.

Still, she said in places with a high incidence of dengue fever, such as the Philippines, where nine out of 10 children aged 9 to 14 are infected by the virus before adolescence, "the potential benefits of vaccination outweigh the potential risks in individuals with unknown serostatus."

Sanofi says it is cooperating with gov't on dengue vaccine
Dr. Ng Su-Peing, global medical head at Sanofi Pasteur, the manufacturer of dengue vaccine Dengvaxia, gestures at a news conference in suburban Taguig city, east of Manila, Philippines Monday, Dec. 4, 2017. The manufacturer of the dengue vaccine whose use was suspended by the Philippines last week after a study showed risks of severe cases in people without previous infection says it is working to resolve those fears. (AP Photo/Bullit Marquez)

Out of 100 people infected by dengue, only 25 typically show symptoms, she told reporters.

Ng said most participants in the study without previous dengue infection who fell ill had cases that ranked in the milder two of four levels of severity. No cases in the most severe level were recorded, and all those stricken with dengue in the study have fully recovered, she said.

Health Secretary Francisco Duque III said the Philippines will wait for a recommendation to be released on Dec. 12 or 13 by the Strategic Advisory Group of Experts on immunization, an advisory body of the World Health Organization.

Ching Santos, general manager of Sanofi Pasteur in the Philippines, said the company has begun sharing the new data with all stakeholders, including private health care professionals, and will cooperate with Philippine authorities in an ongoing review of the public vaccination program.

Sanofi says it is cooperating with gov't on dengue vaccine
Dr. Ng Su-Peing, global medical head at Sanofi Pasteur, the manufacturer of dengue vaccine Dengvaxia, holds documents following a news conference Monday, Dec. 4, 2017 in suburban Taguig city, east of Manila, Philippines. The manufacturer of the dengue vaccine whose use was suspended by the Philippines last week after a study showed risks of severe cases in people without previous infection says it is working to resolve those fears. (AP Photo/Bullit Marquez)

Sanofi is also working with the Philippine Food and Drugs Administration to update product labels to reflect the new information, she added.

Dengue is a mosquito-borne viral infection found in tropical and subtropical climates worldwide. It causes a flu-like disease that can cause joint pain, nausea, vomiting and a rash. In severe cases, dengue can cause breathing problems, hemorrhaging and organ failure.

The World Health Organization says about half the world's population is at risk of , with a recent estimate indicating 390 million infections per year, of which about 96 million people show symptoms.

Explore further: Dengue vaccine not deadly: Sanofi, Philippines

Related Stories

Dengue vaccine not deadly: Sanofi, Philippines

December 4, 2017
A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday.

New dengue vaccine could worsen disease in some people

November 30, 2017
Drugmaker Sanofi says that its dengue vaccine, the world's first, should only be given to people who have previously been sickened by the virus, according to new long-term data.

Philippines suspends world-first dengue vaccine (Update)

December 1, 2017
The Philippines said Friday it had suspended use of a landmark vaccine for the potentially deadly dengue virus after its manufacturer warned it could worsen the disease in some cases.

Philippines 'prepared for worst' in dengue vaccine concerns

December 2, 2017
The Philippines is prepared for a "worst-case scenario" following warnings that an anti-dengue vaccine administered to thousands of children may worsen the disease in some cases, a health official said Saturday.

First dengue vaccine goes on sale in Guatemala

November 22, 2016
The world's first vaccine against dengue, a mosquito-borne virus that causes fever and pain and can be fatal, will go on sale in Guatemala within weeks, the French company making it said Tuesday.

Philippines launches world's first mass dengue vaccination

April 4, 2016
The Philippines on Monday launched the first public immunization program for dengue fever, seeking to administer to a million schoolchildren the world's first licensed vaccine against a mosquito-borne disease that the World ...

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.